Gracell inks $85 mln Series B
China-based Gracell, a cellular gene therapy company, has secured $85 million in Series B funding. Temasek led the round with participation from Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.
25 February 2019•1 min read
